Home›Trial›NCT05820672
NCT05820672RECRUITING

A US Non-interventional, Effectiveness and Safety Study of Patients Treated With SKYTROFA

Study Summary

The goal of this study is to genrate evidence on long-term effectiveness and safety of SKYTROFA (lonapegsomatropin) in patients with growth hormone deficiency under routine clinical care

Conditions
Growth Hormone Deficiency
Interventions / Drugs
No intervention
View on ClinicalTrials.gov ↗
Sponsor
ASND
Ascendis Pharma
Rare Endocrine
D39/100
Study Details
Enrollment900 participants
Primary Completion—
Lead SponsorAscendis Pharma Endocrinology Division A/S
Data Retrieved2026-04-11 02:54:40.919387+00:00
What This Trial Means for Biotech Investors
Trial Phase Context
Status & Expected Data

Currently recruiting: the trial is enrolling patients. A data readout is not expected until after enrollment closes and the follow-up period is complete.

Enrolled: 900 participants
Sponsor Catalyst Profile

Ascendis Pharma (ASND) is the sponsoring company for this trial. BiotechSign currently grades this company D (39/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

ASND Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.